Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Gemcitabine/Cisplatin + IO in Advanced BTC
NCT06708858Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in biliary tract cancer (BTC). Primary endpoint: Objective Response Rate at 1 year. Started Aug 2024; status: recruiting.
02
Drugs
surufatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06708858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708858.